Jun 19, 2015
Combining Stem Cells & Gene Therapy for a ‘Smart’ Sight-Saving Treatment
Dr. Andras Nagy is world-renowned for discovering a method to create stem cells from other cells of the body, a breakthrough which overcame a major hurdle in regenerative medicine. He is also widely recognized for his research that manipulates how cells express different molecules. In his new FBC-funded project, he is using this expertise to transform the treatment of wet age-related macular degeneration (AMD) with a revolutionary plan that would require just a single injection of genetically-modified cells.
In wet-AMD, vision loss is caused by the growth of leaky blood vessels, which is triggered by the over production of a protein called vascular endothelial growth factor (VEGF). For this reason, current treatments focus on administering anti-VEGF drugs (such as Lucentis and Eylea) directly into the eyes, a process that requires regular (monthly or bimonthly) injections. Dr. Nagy’s team recently developed a new anti-VEGF drug which they call “VEGF Sticky-trap.” The team’s long-term objective is to use VEGF Sticky-trap to create a new “smart” cell-based therapy. To do this, they are using stem cells to create eye cells with the ability to secrete VEGF Sticky-trap. They will test if transplanting these cells works as a treatment for wet-AMD. If successful, this strategy of combining cell and gene therapy to deliver drugs has the potential to have a much broader medical impact, far beyond just the treatment of AMD.
Latest FBC News View All
A Message from the President and CEO For 45 years, the Foundation Fighting Blindness has raised and directed critical funding into sight-saving research for blinding eye diseases. From our earliest days as…Read More
This year, participants in Cycle for Sight events across the country set off on exciting routes through farmland, fields, and country lanes. As with any adventure, our cyclists occasionally came across the…Read More
Alongside our partners at the Canadian Retina Society, the Canadian Council of the Blind, and Novartis, we’re raising awareness about the signs and symptoms of age-related macular degeneration. Check out our PSA,…Read More
This month, the Inherited Retinal Dystrophies Consortium Operating for the Under-Represented for Novel Therapies and Services (IRD COUNTS) released a landmark study highlighting the personal costs of living with an inherited retinal…Read More
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our eNews.